The Pfizer-BioNTech vaccine retains the vast majority of its efficacy against the main mutations of the English and South African variants of the coronavirus causing Covid-19, the two companies announced Thursday in a statement.
Read also: Will Covid-19 variants make re-infections more frequent?
In vitro tests "
have not shown the need for a new vaccine to deal with emerging variants,
" according to the companies, which however stress that they "
continue to monitor emerging variants and are ready to respond
" if a of these mutations was resistant to the vaccine.